Compare Bristol-Myers Squibb Co (BMY) vs Chart Industries Inc (GTLS) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

GTLS trades at $209.79, showing minimal daily movement with a -0.04% decline. The stock maintains a bullish technical signal despite recent earnings misses, with Q2 2026 results pending. Valuation metrics show elevated P/E at 629.67 but reasonable P/S at 2.33. The company faces profitability challenges with negative net income margin and ROE, though operating cash flow remains positive at $293M. Recent news highlights Baker Hughes' $13.6 billion acquisition progressing through regulatory approval.

The outlook remains cautiously optimistic given strong analyst support (54% buy rating) and the pending acquisition catalyst. However, consecutive earnings misses and negative profitability metrics present near-term risks. The technical setup suggests potential support at current levels, but fundamental improvement is needed to justify the premium valuation multiple.